Ogilvie’s syndrome—is there a cutoff diameter to proceed with upfront surgery?

Katharina Joechle1 · Jessica Guenzle1 · Stefan Utzolino1 · Stefan Fichtner-Feigl1 · Lampros Kousoulas1

Received: 7 June 2021 / Accepted: 8 December 2021 / Published online: 12 January 2022
© The Author(s) 2022

Abstract

Purpose Although Ogilvie’s syndrome was first described about 70 years ago, its etiology and pathogenesis are still not fully understood. But more importantly, it is also not clear when to approach which therapeutic strategy.

Methods Patients who were diagnosed with Ogilvie’s syndrome at our institution in a 17-year time period (2002–2019) were included and retrospectively evaluated regarding different therapeutical strategies: conservative, endoscopic, or surgical.

Results The study included 71 patients with 21 patients undergoing conservative therapy, 25 patients undergoing endoscopic therapy, and 25 patients undergoing surgery. However, 38% of patients (n = 8) who were primarily addressed for conservative management failed and had to undergo endoscopy or even surgery. Similarly, 8 patients (32%) with primarily endoscopic treatment had to proceed for surgery. In logistic regression analysis, only a colon diameter ≥11 cm (p = 0.01) could predict a lack of therapeutic success by endoscopic treatment. Ninety-day mortality and overall survival were comparable between the groups.

Conclusion As conservative and endoscopic management fail in about one-third of patients, a cutoff diameter ≥11 cm may be an adequate parameter to evaluate surgical therapy.

Keywords Ogilvie · Ogilvie’s syndrome · Acute colonic pseudo-obstruction · Colonic dilatation

Introduction

The first cases of acute colonic pseudo-obstruction were described in 1948 by Sir Heneage Ogilvie [1], therefore known as Ogilvie’s syndrome. It is defined as dilatation of a part or all of the colon without any mechanical obstruction or underlying organic disease such as acute colitis [2]. Although the pathophysiology is still not fully understood and multiple theories are discussed including a denervation of the autonomic nervous system, a vascular and hormonal impact, and metabolic, pharmacological, and infectious reasons [2], it is notable that it mainly occurs in hospitalized patients who are in about one-fifth treated following childbirth, pelvic/orthopedic surgery, or spinal cord trauma [3]. Not only the pathophysiology of Ogilvie’s syndrome remains unclear but also the optimal treatment approach. There are different strategies including restrictive management addressing potentially underlying conditions such as electrolyte repletion or termination of narcotics and opioids [2, 3] and placing a nasogastric tube for gastrointestinal decompression. Even if this management is recommended for 48–72 h after diagnosis of Ogilvie’s syndrome by the guidelines of the American Society for Gastrointestinal Endoscopy [4], the severe risk of colonic perforation or ischemia must be always reminded, increasing by increased colon diameter [2] and leading to a high mortality rate of about 40–50% [5]. Therefore, it is crucial to identify the correct time point to approach the adequate next therapeutic step to lower morbidity and mortality associated with Ogilvie’s syndrome. In this context, we aimed to identify factors predicting a successful outcome after the different therapeutic strategies.
Material and methods

Study population

After obtaining permission from the institutional ethics committee (protocol number 339/20), we retrospectively identified patients who were diagnosed and treated for Ogilvie’s syndrome at our institution between 2002 and 2019 by searching for the ICD10 code K56.0. As this code not only includes Ogilvie’s syndrome but also paralysis or paralytic ileus, these patients were checked by the authors to fulfill the criteria of Ogilvie’s syndrome. Patients with primary Ogilvie’s syndrome as well as patients who developed Ogilvie’s syndrome postoperatively were included in this study.

Patients were divided into three groups regarding the treatment strategy they received: first, conservative treatment including proximal gastrointestinal decompression via nasogastric tube, intravenous fluid, and electrolyte repletion and pharmacologic therapy to restrain bowel motility (neostigmine, Gastrografine, erythromycin, etc.); second, endoscopic treatment with or without placing of a decompression tube; and third, surgical therapy including surgical decompression with and without colonic resection.

Therapeutic failure was defined as being in need to undergo endoscopy or surgery for the conservatively treated patients and being in need to undergo surgery for the endoscopically treated patients.

Definitions

Ogilvie’s syndrome was defined as dilatation of a part or all of the colon without any mechanical obstruction or underlying organic disease such as acute colitis. The diameter of colonic dilatation was measured on computer tomography (CT) scans for the majority of patients (80%). For the other 20% of patients who did not have a CT scan available, an abdominal X-ray was used for the measurement of colonic dilatation in a standardized procedure.

If the initially chosen treatment strategy was not successful and patients had to proceed to a more invasive treatment, it was defined as therapeutic failure. Thus, treatment failure for patients with initial conservative treatment strategy included to be in need for undergoing endoscopy and/or even surgery and for patients who were primarily addressed for endoscopy if they were in need for surgery.

Data collection

The following patient data were recorded and the study reported in line with STROCSS criteria [6]: sex, age, comorbidities, reason for hospital admission, time frame between hospital admission and diagnosis of Ogilvie’s syndrome, blood counts of leukocytes, CRP, procalcitonin and lactate at the time of diagnosis of Ogilvie’s syndrome, colonic dilatation in cm, treatment strategy (conservative vs endoscopic vs surgical), number of endoscopies, placement of a decompression tube, reason for surgery, kind of operation, length of stay on intensive care unit (ICU), readmission on ICU, length of hospital stay, 90-day mortality, and survival data counted from the day of diagnosis of Ogilvie’s syndrome.

Statistical analysis

Statistical analysis was performed using SPSS statistics version 25 (IBM, Armonk, New York, USA). Continuous variables were analyzed using the Mann–Whitney-U test and the Kruskal–Wallis test and expressed as medians and ranges. Categorical variables were analyzed using the $\chi^2$ test or Fisher’s exact test, as appropriate, and expressed as absolute values and percentages. Logistic regression analysis was used to predict factors of therapeutic failure for conservative and endoscopic treatment with a cutoff $p$-value of $<0.05$ in univariate logistic regression to include factors into multivariate logistic regression. Overall survival (OS) rates were calculated from the day of diagnosis of Ogilvie’s syndrome, estimated using the Kaplan–Meier method, and compared using log-rank statistics. All tests were two-sided and a $p$ value $<0.05$ was considered to be statistically significant.

Results

Patient characteristics

Between 2002 and 2019, 71 patients were treated for Ogilvie’s syndrome at our institution. Of these, 21 patients (30%) underwent conservative treatment, 25 patients (35%) underwent endoscopic treatment, and 25 patients (35%) underwent upfront surgery. Patient characteristics of the three groups are shown in Table 1. The median age of the cohort was 67 years (18–92) with Ogilvie’s syndrome occurring more often in male than female patients throughout the groups. The primary reasons for hospital admission were similar between the three groups except for abdominal symptoms ($p = 0.03$) which was noticed to occur more often in patients who had to undergo upfront surgery. Primary Ogilvie’s syndrome was noticed in 37 patients (52%) and 34 patients (48%) developed Ogilvie’s syndrome postoperatively. Of those, 12 patients underwent trauma or orthopedic surgery, 16 had abdominal surgery, and 6 patients developed Ogilvie’s syndrome after vascular or cardiac surgery. Liver surgery as a known risk factor for Ogilvie’s syndrome did not occur in our cohort, but in 12 cases patients developed postoperative Ogilvie’s...
syndrome after elective abdominal surgery and in 4 cases after emergency abdominal surgery (appendicitis, cholecystitis, perforation, and bleeding). Almost all patients (n = 65, 92%) had comorbidities with chronic kidney disease significantly differing between the groups (p = 0.04) and occurring the most often in patients who underwent endoscopic treatment. Whereas colon dilatation was comparable between the groups (p = 0.76), they significantly differed regarding blood levels of CRP (p = 0.03), lactate (p = 0.04), and leukocytes (p = 0.02) at the time of diagnosis. There was also a statistically significant difference regarding the length of hospital stay (p = 0.02). However, comparing only endoscopic and surgical treatment, the length of hospital stay was comparable (p = 0.43). For length of ICU stay (p = 0.21) and readmission rate to ICU (p = 0.92), there was no significant difference between the groups as well as for 90-day mortality (p = 0.98).

Table 1  Patient characteristics

|                         | Total n = 71 (100%) | Conservative therapy n = 21 (30%) | Endoscopic therapy n = 25 (35%) | Operative therapy n = 25 (35%) | p value |
|-------------------------|---------------------|-----------------------------------|---------------------------------|---------------------------------|---------|
| Age in years, median (range) | 67 (18–92)          | 75 (18–92)                        | 64 (34–86)                       | 60 (21–83)                       | 0.20    |
| Gender, n (%)           |                     |                                   |                                 |                                 |         |
| Male                    | 52 (73)             | 17 (81)                           | 19 (76)                          | 16 (64)                          | 0.40    |
| Female                  | 19 (27)             | 4 (19)                            | 6 (24)                           | 9 (36)                           |         |
| Primary reason for admission, n (%) |                 |                                   |                                 |                                 |         |
| Trauma                  | 14 (20)             | 6 (29)                            | 5 (20)                           | 3 (12)                           | 0.37    |
| Abdominal focus         | 31 (44)             | 9 (38)                            | 7 (28)                           | 16 (64)                          | 0.03    |
| Oncologic reason (CTx, etc.) | 6 (8)               | 2 (10)                            | 3 (12)                           | 1 (4)                            | 0.58    |
| Internal medicine       | 6 (8)               | 1 (5)                             | 3 (12)                           | 2 (8)                            | 0.68    |
| Cardiac/vascular        | 11 (16)             | 3 (14)                            | 6 (24)                           | 2 (8)                            | 0.29    |
| Neurological/psychiatric| 3 (4)               | 1 (5)                             | 1 (4)                            | 1 (4)                            | 0.99    |
| Comorbidities, n (%)    | 65 (92)             | 20 (95)                           | 23 (92)                          | 22 (88)                          | 0.68    |
| Arterial hypertension   | 24 (34)             | 8 (38)                            | 8 (32)                           | 8 (32)                           | 0.88    |
| CAD                     | 13 (18)             | 5 (24)                            | 5 (20)                           | 3 (12)                           | 0.57    |
| PAD                     | 6 (9)               | 2 (10)                            | 2 (8)                            | 2 (8)                            | 0.98    |
| Atrial fibrillation     | 9 (13)              | 2 (10)                            | 3 (12)                           | 4 (16)                           | 0.80    |
| Stroke                  | 10 (14)             | 2 (10)                            | 4 (16)                           | 4 (16)                           | 0.77    |
| Cancer                  | 24 (34)             | 8 (38)                            | 10 (40)                          | 6 (24)                           | 0.43    |
| Previous abdominal surgery | 20 (28)            | 5 (24)                            | 9 (36)                           | 6 (24)                           | 0.56    |
| Chronic kidney disease  | 12 (17)             | 2 (10)                            | 8 (32)                           | 2 (8)                            | 0.04    |
| Pulmonary disorders     | 18 (25)             | 8 (38)                            | 7 (28)                           | 3 (12)                           | 0.12    |
| Diabetes                | 11 (16)             | 2 (10)                            | 3 (12)                           | 6 (24)                           | 0.34    |
| Obesity                 | 10 (14)             | 3 (14)                            | 3 (12)                           | 4 (16)                           | 0.92    |
| Alcohol abuse           | 9 (13)              | 1 (5)                             | 3 (12)                           | 5 (20)                           | 0.30    |
| Psychiatric disorders   | 21 (30)             | 9 (43)                            | 4 (16)                           | 8 (32)                           | 0.13    |
| Days from hospital admission to diagnosis, median (range) | 3 (0–44) | 3 (0–44) | 6 (0–21) | 3 (0–15) | 0.14 |
| Leukocytes at diagnosis, cells/nl, median (range)# | 11.2 (2.5–35.6) | 9.7 (3.1–26.4) | 14.1 (7.5–35.6) | 9.8 (2.5–23.9) | 0.02 |
| CRP at diagnosis, mg/L, median (range)* | 116 (3–495) | 27 (3–495) | 150 (4–312) | 231 (3–495) | 0.03 |
| Lactate at diagnosis, mmol/L, median (range)* | 1.6 (0.6–10.1) | 1.3 (0.6–4.8) | 1.6 (0.7–3.8) | 2.3 (0.7–10.1) | 0.04 |
| Dilatation of colon in cm, median (range)~ | 9 (6–15) | 9 (7–12) | 9 (6–13) | 8 (7–15) | 0.76 |
| Length of stay on ICU, days, median (range) | 5 (0–49) | 4 (0–22) | 6 (0–49) | 7 (1–47) | 0.21 |
| Readmission on ICU, n (%) | 18 (25) | 6 (29) | 6 (24) | 6 (24) | 0.92 |
| Length of hospital stay, days, median (range) | 26 (4–127) | 10 (4–78) | 29 (4–71) | 27 (7–127) | 0.02 |
| 90-day mortality, n (%) | 11 (20) | 3 (21) | 3 (19) | 5 (21) | 0.98 |

CTx, chemotherapy; CAD, coronary artery disease; ICU, intensive care unit; PAD, peripheral artery disease; CRP, c-reactive protein; #missing for 51 patients, *missing for 6 patients, °missing for 28 patients, ~missing for 22 patients
Conservative management

Conservative treatment was successful for 13 patients (62%) and failed for the remaining 8 patients (38%) who subsequently had to undergo endoscopy ($n=2$, 9.5%), surgery ($n=4$, 19%), or both endoscopy and surgery ($n=2$, 9.5%).

Comparing patients with and without successful conservative management (Table 2) showed that therapeutic failure leads to a significantly higher readmission rate in ICU ($p=0.01$) and a significantly longer hospital stay ($p=0.002$). Performing a logistic regression analysis did not identify any predictor of therapeutic failure for patients undergoing conservative management (Table 3).

Endoscopic management

In patients who underwent endoscopic treatment, a decompression tube was placed for 19 patients (76%), and in 10 patients (40%), a re-endoscopy was necessary. Similar to the conservative treatment group, 8 patients (32%) could not be treated successfully by endoscopy and were in need to undergo surgery due to the lack of endoscopic success.

| Table 2 | Characteristics of patients with and without therapeutic success receiving upfront conservative management |
|-----------------|---------------------------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
|                | Total $n=21$ (100%) | Therapeutic success $n=13$ (62%) | No therapeutic success $n=8$ (38%) | $p$ value |
| Age in years, median (range) | 75 (18–92) | 77 (29–92) | 74 (18–79) | 0.44 |
| Gender, n (%) | | | | |
| Male | 17 (81) | 10 (77) | 7 (88) | 0.64 |
| Female | 4 (19) | 3 (23) | 1 (12) | |
| Primary reason for admission, n (%) | | | | |
| Trauma | 6 (29) | 2 (15) | 4 (50) | 0.15 |
| Abdominal focus | 9 (38) | 6 (46) | 2 (25) | 0.40 |
| Oncologic reason (CTx, etc.) | 2 (10) | 1 (8) | 1 (12) | 1.0 |
| Internal medicine | 1 (5) | 1 (8) | 0 (0) | 1.0 |
| Cardiac/vascular | 3 (14) | 2 (15) | 1 (12) | 1.0 |
| Neurological/psychiatric | 1 (5) | 1 (8) | 0 (0) | 1.0 |
| Comorbidities, n (%) | | | | |
| Arterial hypertension | 8 (38) | 5 (38) | 3 (38) | 1.0 |
| CAD | 5 (24) | 2 (15) | 3 (38) | 0.33 |
| PAD | 2 (10) | 0 (0) | 2 (25) | 0.13 |
| Atrial fibrillation | 2 (10) | 1 (8) | 1 (12) | 1.0 |
| Stroke | 2 (10) | 2 (15) | 0 (0) | 0.51 |
| Cancer | 8 (38) | 4 (31) | 4 (50) | 0.65 |
| Previous abdominal surgery | 5 (24) | 3 (23) | 2 (25) | 1.0 |
| Chronic kidney disease | 2 (10) | 0 (0) | 2 (25) | 0.13 |
| Pulmonary disorders | 8 (38) | 5 (38) | 3 (38) | 1.0 |
| Diabetes | 2 (10) | 1 (8) | 1 (12) | 1.0 |
| Obesity | 3 (14) | 2 (15) | 1 (25) | 1.0 |
| Alcohol abuse | 1 (5) | 1 (8) | 0 (0) | 1.0 |
| Psychiatric disorders | 9 (43) | 6 (46) | 3 (38) | 1.0 |
| Days from hospital admission to diagnosis, median (range) | 3 (0–44) | 1 (0–44) | 3 (0–9) | 0.29 |
| Leukocytes at diagnosis, cells/nl, median (range)* | 9.7 (3.1–26.4) | 10.3 (3.8–21) | 9.0 (3.1–26.4) | 0.72 |
| CRP at diagnosis, mg/L, median (range)~ | 27 (3–495) | 21 (3–83) | 123 (3.0–495) | 0.09 |
| Lactate at diagnosis, mmol/L, median (range)* | 1.3 (0.6–4.8) | 1.5 (0.6–4.8) | 1.1 (1.0–1.3) | 0.41 |
| Dilatation of colon in cm, median (range)~ | 9 (7–12) | 9 (7–12) | 9.5 (8–12) | 0.32 |
| Length of stay on ICU, days, median (range) | 4 (0–22) | 4 (0–6) | 5 (2–22) | 0.11 |
| Readmission on ICU, n (%) | 6 (29) | 1 (8) | 5 (63) | 0.01 |
| Length of hospital stay, days, median (range) | 10 (4–78) | 5 (4–78) | 27 (10–66) | 0.002 |
| 90-day mortality, n (%) | 3 (21) | 0 (0) | 3 (38) | 0.21 |

CTx, chemotherapy; CAD, coronary artery disease; ICU, intensive care unit; PAD, peripheral artery disease; CRP, c-reactive protein; *missing for 2 patients, ~missing for 6 patients, °missing for 16 patients, *missing for 10 patients
Table 3 Logistic regression analysis predicting the lack of therapeutic success in patients receiving upfront conservative management

|                                | Univariate |     |
|--------------------------------|------------|-----|
|                                | OR         | CI  |
| Age ≥ 65 years                 | 4.4        | 0.47-47.0 | 0.22 |
| Gender female                  | 0.476      | 0.04-5.6 | 0.56 |
| Primary reason for admission   |            |       |
| Trauma                         | 5.5        | 0.71-42.6 | 0.10 |
| Abdominal focus                | 0.389      | 0.06-27.0 | 0.34 |
| Oncologic reason (CTx, etc.)   | 1.7        | 0.09-31.9 | 0.72 |
| Internal medicine              | 0.0        | 0      | 1.00 |
| Cardiac/vascular               | 0.786      | 0.06-10.4 | 0.86 |
| Neurological/psychiatric       | 0.0        | 0      | 1.00 |
| Comorbidities                  |            |       |
| Arterial hypertension          | 0.96       | 0.16-5.9 | 0.97 |
| CAD                            | 3.3        | 0.41-26.4 | 0.26 |
| PAD                            | 0.0        | 0      | 1.00 |
| Atrial fibrillation            | 1.7        | 0.09-31.9 | 0.72 |
| Stroke                         | 0.0        | 0      | 1.00 |
| Cancer                         | 2.3        | 0.4-13.9 | 0.38 |
| Previous abdominal surgery     | 1.1        | 0.14-8.7 | 0.92 |
| Chronic kidney disease         | 0.0        | 0      | 1.00 |
| Pulmonary disorders            | 0.960      | 0.2-5.9 | 0.97 |
| Diabetes                       | 1.7        | 0.09-31.9 | 0.72 |
| Obesity                        | 0.8        | 0.06-10.4 | 0.86 |
| Alcohol abuse                  | 0.0        | 0      | 1.00 |
| Psychiatric disorders          | 0.7        | 0.1-4.2 | 0.7  |
| Colon dilatation ≥ 9 cm        | 4          | 0.3-49.6 | 0.28 |
| Colon dilatation ≥ 10 cm       | 1.25       | 0.15-9.9 | 0.83 |
| Colon dilatation ≥ 11 cm       | 4          | 0.3-58.6 | 0.31 |
| Leukocytosis ≥ 10 cells/nl at diagnosis | 0.72 | 0.1-4.6 | 0.73 |
| CRP ≥ 100 mg/L at diagnosis    | 0.0        | 0      | 1.00 |
| Lactate ≥ 2 mmol/L at diagnosis| 0.0        | 0      | 1.00 |

CTx, chemotherapy; CAD, coronary artery disease; PAD, peripheral artery disease; CRP, c-reactive protein

(n = 1) or the occurrence of complications (n = 7). Complications included ischemia (n = 1), colonic perforation (n = 5), or both (n = 1).

Comparing patients who were and were not treated successfully by endoscopy (Table 4) showed that patients with therapeutic failure had a significantly higher diameter of colon dilatation (p = 0.001). Performing a logistic regression analysis identified a colon diameter ≥ 11 cm being the only factor to predict therapeutic failure of endoscopic treatment for Ogilvie’s syndrome (Table 5).

Surgical therapy

Reasons for upfront surgery were mainly acute abdomen (n = 12, 17%) followed by colonic perforation (n = 3, 12%) and sepsis (n = 3, 12%). Whereas for 20 patients (80%), an operative decompression (appendectomy, colotomy, ileo- or colostomy, or manual decompression) was performed; only 5 patients (20%) were in need of resection. A re-operation was necessary for 3 patients (12%) because of ischemia. Postoperative complications occurred in 84% of patients (n = 22) with a major complication (Dindo-Clavien classification ≥ IIIa) in 72% of patients (n = 19). Ninety-day mortality was 21% (n = 5).

Overall survival

Mean overall survival was 22 months and comparable between the groups (p = 0.81; Fig. 1). Also for patients who were and were not treated successfully by conservative or endoscopic treatment, there was no difference in OS (conservative success vs failure p = 0.45; endoscopic success vs failure p = 0.89; Figs. 2 and 3).

Discussion

This study shows that in patients with Ogilvie’s syndrome treatment failure is a quite common risk no matter if conservative treatment or endoscopy was the preferred therapeutic strategy. About one-third of patients in the conservative group had to proceed to endoscopy and/or surgery. Similarly, also about one-third of patients in the endoscopic group was in need to undergo surgery. However, the only factor to predict treatment failure was a colon diameter ≥ 11 cm in patients who were treated endoscopically.

Usually, surgery is the last step to take in patients with Ogilvie’s syndrome except they present with colonic perforation, ischemia, peritonitis, or sepsis. In this study, this was the case for 35% of the study population (25 patients) at the time of diagnosis of Ogilvie’s syndrome and these patients subsequently underwent upfront surgery. However, these patients suffered a high postoperative morbidity with 72% (n = 19) of patients having major complications with sepsis/septic shock, respiratory insufficiency, and burst abdomen occurring most often in our cohort. Therefore, the identified cutoff parameter of colonic dilatation of 11 cm might be appropriate to first lower the incidence of colonic perforation, ischemia, and sepsis and secondly to also reduce postoperative complications if patients are referred to surgery at an earlier stage instead to proceed with endoscopy. Similarly, the guidelines of the American Society for Gastrointestinal Endoscopy [4] recommend a caecal diameter > 12 cm to refer patients to surgery as otherwise the risk of perforation was significantly increased in a study by Vanek et al. [3]. Other risk factors described to predict endoscopic failure were female gender, emergent admission and metastatic cancer, and COPD as comorbidities [4]. Although almost all of
the patients of our study population had severe comorbidities, this study could not identify any comorbidity to predict therapeutic failure. Regarding the decision to perform surgery for the treatment of patients with Ogilvie’s syndrome, the patients’ clinical presentation could clearly impact the decision-making. Recommending surgery for an asymptomatic patient with a colonic dilatation of 11 cm or more is a really challenging decision. However, our study clearly presented, that even these asymptomatic patients are at high risk for the development of colonic ischemia and perforation. In our study population, over 50% of the patients with a colonic dilation of 11 cm or more who were primarily treated conservatively or by endoscopy did not respond to the therapy and had consequently undergone surgery. Therefore, we clearly recommend surgery as the therapy to choose in asymptomatic patients with a colonic dilation $\geq 11$ cm, especially if patients have further risk factors such as immunosuppressive therapy.

Not only for endoscopic but also for conservative management, the failure rates are quite high with over 30%. However, there must be noted that the definitions of treatment failure are different for the two groups. In patients with

Table 4 Characteristics of patients with and without therapeutic success in receiving upfront endoscopic management

| Characteristic                                      | Total $n=25$ (100%) | Therapeutic success $n=17$ (68%) | No therapeutic success $n=8$ (32%) | $p$ value |
|----------------------------------------------------|---------------------|----------------------------------|-----------------------------------|-----------|
| Age in years, median (range)                        | 64 (34–86)          | 67 (34–86)                       | 62 (45–71)                        | 0.35      |
| Gender, $n$ (%)                                      |                     |                                  |                                   |           |
| Male                                                | 19 (76)             | 13 (76)                          | 6 (75)                            | 1.0       |
| Female                                              | 6 (24)              | 4 (24)                           | 2 (25)                            |           |
| Primary reason for admission, $n$ (%)                |                     |                                  |                                   |           |
| Trauma                                              | 5 (20)              | 3 (18)                           | 2 (25)                            | 1.0       |
| Abdominal focus                                      | 7 (28)              | 5 (29)                           | 2 (25)                            | 1.0       |
| Oncologic reason (CTx, etc.)                        | 3 (12)              | 3 (18)                           | 0 (0)                             | 0.53      |
| Internal medicine                                    | 3 (12)              | 2 (12)                           | 1 (12)                            | 1.0       |
| Cardiac/vascular                                     | 6 (24)              | 3 (18)                           | 3 (38)                            | 0.34      |
| Neurological/psychiatric                             | 1 (4)               | 1 (6)                            | 0 (0)                             | 1.0       |
| Comorbidities, $n$ (%)                               | 23 (92)             | 17 (100)                         | 6 (75)                            | 0.09      |
| Arterial hypertension                               | 8 (32)              | 7 (41)                           | 1 (12)                            | 0.21      |
| CAD                                                 | 5 (20)              | 4 (24)                           | 1 (12)                            | 0.64      |
| PAD                                                 | 2 (8)               | 1 (6)                            | 1 (12)                            | 1.0       |
| Atrial fibrillation                                 | 3 (12)              | 1 (6)                            | 2 (25)                            | 0.23      |
| Stroke                                              | 4 (16)              | 2 (12)                           | 2 (25)                            | 0.57      |
| Cancer                                               | 10 (40)             | 9 (53)                           | 1 (12)                            | 0.09      |
| Previous abdominal surgery                           | 9 (36)              | 7 (41)                           | 2 (25)                            | 0.66      |
| Chronic kidney disease                              | 8 (32)              | 6 (35)                           | 2 (25)                            | 0.68      |
| Pulmonary disorders                                  | 7 (28)              | 4 (24)                           | 3 (38)                            | 0.64      |
| Diabetes                                             | 3 (12)              | 3 (18)                           | 0 (0)                             | 0.53      |
| Obesity                                              | 3 (12)              | 1 (6)                            | 2 (25)                            | 0.23      |
| Alcohol abuse                                        | 3 (12)              | 3 (18)                           | 0 (0)                             | 0.53      |
| Psychiatric disorders                                | 4 (16)              | 3 (18)                           | 1 (12)                            | 1.0       |
| Days from hospital admission to diagnosis, median (range) | 6 (0–21)          | 5 (0–21)                         | 6 (1–9)                           | 0.97      |
| Leukocytes at diagnosis, cells/nl, median (range)§   | 14.1 (7.5–35.6)     | 13.7 (7.5–35.6)                  | 16.1 (7.7–22.6)                   | 0.70      |
| CRP at diagnosis, mg/L, median (range)*             | 150 (4–312)         | 93 (4–312)                       | 160 (116–246)                     | 0.60      |
| Lactate at diagnosis, mmol/L, median (range)°       | 1.6 (0.7–3.8)       | 1.6 (0.7–3.8)                    | 1.4 (0.9–1.9)                     | 0.34      |
| Dilatation of colon in cm, median (range)~           | 9 (6–13)            | 9 (6–11)                         | 12 (10–13)                        | 0.001     |
| Length of stay on ICU, days, median (range)          | 6 (0–49)            | 5 (0–49)                         | 8 (1–28)                          | 0.83      |
| Readmission on ICU, $n$ (%)                          | 6 (24)              | 3 (18)                           | 3 (38)                            | 0.34      |
| Length of hospital stay, days, median (range)        | 29 (4–71)           | 27 (4–71)                        | 45 (26–64)                        | 0.09      |
| 90-day mortality, $n$ (%)                            | 3 (19)              | 2 (12)                           | 1 (12)                            | 1.0       |

CTx, chemotherapy; CAD, coronary artery disease; ICU, intensive care unit; PAD, peripheral artery disease; CRP, c-reactive protein; §missing for 3 patients, *missing for 12 patients, #missing for 20 patients, °missing for 7 patients, ~missing for 4 patients
conservative treatment might be the first therapy of choice because a significant number of patients responded to this treatment with the welcome association of a shorter length of stay. These results are supported by the newest guidelines who recommend medical therapy before proceeding with endoscopy [4]. However, if conservative therapy or endoscopy is the better treatment strategy for patients with Ogilvie’s syndrome, it was examined by two studies which both concluded endoscopy to be superior to medical therapy [7, 8]. Endoscopy was not only more effective compared to the medical therapy [7, 8] but also the chance of avoiding a second treatment modality was higher [7]. A review examining this matter found the endoscopic and medical treatment to be comparable [9]. No matter, if conservative or endoscopic treatment is chosen for upfront therapy, a close and interdisciplinary patient observation is necessary for our opinion not to miss the right time point for a more aggressive treatment strategy. This might be necessary if the colonic diameter is not decreasing, clinical symptoms or lab results are worsening.

This study has some limitations. First, the retrospective, single-institutional design with a selective cohort of patients leads to the risk of selection bias. Therefore, it is possible that patients with more severe comorbidities might have been treated more aggressively compared to healthier patients. Second, the small study population in a long study period of 17 years in which therapeutic strategies might have changed. However, Ogilvie’s syndrome is a quite uncommon disease; therefore, only few publications with a higher number of patients exist.

### Conclusion

Conservative and endoscopic treatment strategies fail in over 30% of patients. As treatment failure increases the severe risk of colonic perforation and ischemia a cutoff diameter of colon dilatation of 11 cm might be appropriate to refer patients to surgery and not to proceed with endoscopy.

---

**Table 5** Logistic regression analysis predicting the lack of therapeutic success in patients receiving upfront endoscopic management

| Univariate | OR    | CI     | p value |
|------------|-------|--------|---------|
| Age ≥ 65 years | 0.5   | 0.09–2.9 | 0.47    |
| Gender female | 1     | 0.2–7.6  | 0.94    |
| Primary reason for admission |        |         |         |
| Trauma       | 1.6   | 0.2–11.8 | 0.67    |
| Abdominal focus | 0.8   | 0.1–5.4  | 0.82    |
| Oncologic reason (CTx, etc.) | 0.0   | 0.1–1.0  | 1.0     |
| Internal medicine | 1.1   | 0.08–13.9 | 0.96   |
| Cardiac/vascular | 1.8   | 0.4–18.7 | 0.29    |
| Neurological/psychiatric | 0.0   | 0.1–1.0  | 1.0     |
| Comorbidities | 0.0   | 0.1–1.0  | 1.0     |
| Arterial hypertension | 0.2   | 0.02–2.1 | 0.18    |
| CAD          | 0.5   | 0.04–4.9 | 0.53    |
| PAD          | 2.3   | 0.1–41.9 | 0.58    |
| Atrial fibrillation | 5.3   | 0.4–70.2 | 0.20    |
| Stroke       | 2.5   | 0.3–22  | 0.41    |
| Cancer       | 0.1   | 0.01–1.4 | 0.08    |
| Previous abdominal surgery | 0.476 | 0.07–3.1 | 0.44    |
| Chronic kidney disease | 0.6   | 0.09–4.0 | 0.61    |
| Pulmonary disorders | 1.9   | 0.3–12  | 0.47    |
| Diabetes     | 0.0   | 0.1–1.0  | 1.0     |
| Obesity      | 5.3   | 0.4–70.2 | 0.20    |
| Alcohol abuse | 0.0   | 0.1–1.0  | 1.0     |
| Psychiatric disorders | 0.7   | 0.1–7.6  | 0.74    |
| Colon dilation ≥ 9 cm | 0.0   | 0.1–1.0  | 1.0     |
| Colon dilatation ≥ 10 cm | 0.0   | 0.1–1.0  | 1.0     |
| Colon dilation ≥ 11 cm | 28    | 1.9–394  | 0.01    |
| Leukocytosis ≥ 10 cells/nl at diagnosis | 0.8   | 0.1–6.3  | 0.85    |
| CRP ≥ 100 mg/L at diagnosis | 0.0   | 0.1–1.0  | 1.0     |
| Lactate ≥ 2 mmol/L at diagnosis | 0.0   | 0.1–1.0  | 1.0     |

CTx, chemotherapy; CAD, coronary artery disease; PAD, peripheral artery disease; CRP, c-reactive protein
Fig. 1 Overall survival of patients with Ogilvie Syndrome and different therapeutic strategies

Fig. 2 Overall survival of patients with conservative management
**Author's contributions** Katharina Joechle: study conception and design, acquisition of data, analysis and interpretation of data, drafting of the manuscript; Jessica Guenzle: acquisition of data, critical revision of the manuscript; Stefan Utzolino: study conception and design, critical revision of the manuscript; Stefan Fichtner-Feigl: study conception and design, critical revision of the manuscript; Lampros Kousoulas: study conception and design, acquisition of data, analysis and interpretation of data, critical revision of the manuscript.

**Funding** Open Access funding enabled and organized by Projekt DEAL.

**Data Availability** The data that support the findings of this study are available on request from the corresponding author after approval of the institution’s ethics committee. The data are not publicly available due to privacy or ethical restrictions.

**Code availability** Not applicable.

**Declarations**

**Ethics approval** The study protocol and all the procedures were performed according to the institutional ethical standards of the University of Freiburg (reference number 339/20).

**Consent to participate** Not applicable.

**Consent for publication** Not applicable.

**Conflict of interest** The authors declare no competing interests.

---

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

**References**

1. Ogilvie H (1948) Large-intestine colic due to sympathetic deprivation; a new clinical syndrome. Br Med J 2(4579):671–673. https://doi.org/10.1136/bmj.2.4579.671
2. Pereira P, Djeudji F, Leduc P, Fanget F, Barth X (2015) Ogilvie’s syndrome-acute colonic pseudo-obstruction. J Visc Surg 152(2):99–105. https://doi.org/10.1016/j.viscsurg.2015.02.004
3. Vanek VW, Al-Salti M (1986) Acute pseudo-obstruction of the colon (Ogilvie’s syndrome). An analysis of 400 cases. Dis Colon Rectum 29(3):203–10. https://doi.org/10.1007/bf0255027
4. Naveed M, Jamil LH, Fujii-Lau LL, Al-Haddad M, Buxbaum JL, Fishman DS et al (2020) American Society for Gastrointestinal Endoscopy guideline on the role of endoscopy in the management of acute colonic pseudo-obstruction and colonic volvulus. Gastrointest Endosc 91(2):228–235. https://doi.org/10.1016/j.gie.2019.09.007
5. Nanni G, Garbini A, Luchetti P, Nanni G, Ronconi P, Castagneto M (1982) Ogilvie’s syndrome (acute colonic pseudo-obstruction): review of the literature (October 1948 to March 1980) and report
of four additional cases. Dis Colon Rectum 25(2):157–166. https://doi.org/10.1007/bf02553265
6. Agha R, Abdall-Razak A, Crossley E, Dowlut N, Iosifidis C, Mathew G (2019) STROCSS 2019 Guideline: strengthening the reporting of cohort studies in surgery. Int J Surg 72:156–165. https://doi.org/10.1016/j.ijsu.2019.11.002
7. Peker KD, Cikot M, Bozkurt MA, Ilhan B, Kankaya B, Bimboga S et al (2017) Colonoscopic decompression should be used before neostigmine in the treatment of Ogilvie’s syndrome. Eur J Trauma Emerg Surg 43(4):557–566. https://doi.org/10.1007/s00068-016-0709-y
8. Tsirline VB, Zemlyak AY, Avery MJ, Colavita PD, Christmas AB, Heniford BT et al (2012) Colonoscopy is superior to neostigmine in the treatment of Ogilvie’s syndrome. Am J Surg 204(6):849–55. https://doi.org/10.1016/j.amjsurg.2012.05.006 (discussion 55)
9. Bernardi MP, Warrier S, Lynch AC, Heriot AG (2015) Acute and chronic pseudo-obstruction: a current update. ANZ J Surg 85(10):709–714. https://doi.org/10.1111/ans.13148

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.